Methods: Study 350 provided expanded access to BCV for life-threatening dsDNA infections. Most subjects were HCT (72%) or solid organ transplant (16%) recipients, and 25% were enrolled due to concerns of nephrotoxicity. Baseline (BL) and on-treatment Glomerular filtration rates (GFR), estimated using the MDRD4 (adults) and Schwartz (children) formulas, were evaluated in subjects with prior CDV +/-FOS and no concomitant CDV or FOS use, regardless of indication and other nephrotoxic agent use.
Results: Median BL GFR for 37 subjects with prior but no concomitant CDV use was 87 mL/min. Thirty-two (86%) subjects had a maximum GFR>BL during treatment, and had a median of 6 weeks of BCV, compared to 2 weeks for those subjects without GFR improvement. For subjects with BL GFR<60mL/min, 13/14 had max GFR>BL (8/13 had >20mL/min increase); 10/14 subjects had last on-treatment GFR>BL (7/10 had >20mL/min increase). For subjects with BL GFR<30mL/min, 6/6 had max GFR>BL (4/6 had >20mL/min increase); 5/6 had last GFR>BL (4/5 had increase >20mL/min).
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